Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jeffrey Lochhead"'
Autor:
Robert Betterton, Erica I Williams, Joshua Stanton, Jeffrey Lochhead, Tom Davis, Patrick Ronaldson
Publikováno v:
Stroke. 54
Objectives: We have shown that transforming growth factor-β (TGF-β)/activin-like kinase 1 (ALK1) signaling at the blood-brain barrier (BBB) can regulate organic anion transporting polypeptide 1a4 (Oatp1a4), a transporter involved in brain uptake of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9835402b64986f28f1a1d810a461cf8d
https://doi.org/10.1161/str.54.suppl_1.tp209
https://doi.org/10.1161/str.54.suppl_1.tp209
Autor:
Joshua Stanton, Erica I Williams, Robert Betterton, Jeffrey Lochhead, Thomas Davis, Patrick Ronaldson
Publikováno v:
Stroke. 54
Purpose: Cationic drugs have often been considered for stroke treatment but their utility is dependent upondelivery across the blood-brain barrier (BBB). This process can involve transporters for cationic substratessuch as organic cation transporters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dba37c64474fba09ebc0f14a3ee17a6b
https://doi.org/10.1161/str.54.suppl_1.wp244
https://doi.org/10.1161/str.54.suppl_1.wp244
Publikováno v:
Journal of Cerebral Blood Flow & Metabolism; 2023 Suppl 1, Vol. 43, pS84-S197, 114p
Autor:
Pawar, Grishma N.1, Parayath, Neha N.1, Nocera, Angela L.1, Bleier, Benjamin S.2, Amiji, Mansoor M.1 m.amiji@northeastern.edu
Publikováno v:
PLoS ONE. 12/5/2018, Vol. 13 Issue 12, p1-15. 15p.
Autor:
Pizzo, Michelle E., Wolak, Daniel J., Kumar, Niyanta N., Brunette, Eric, Brunnquell, Christina L., Hannocks, Melanie‐Jane, Abbott, N. Joan, Meyerand, M. Elizabeth, Sorokin, Lydia, Stanimirovic, Danica B., Thorne, Robert G.
Publikováno v:
Journal of Physiology; Feb2018, Vol. 596 Issue 3, p445-475, 31p
Autor:
Kumar, Niyanta N.1, Gautam, Mohan1, Lochhead, Jeffrey J.1, Wolak, Daniel J., Ithapu, Vamsi2, Singh, Vikas2, Thorne, Robert G.
Publikováno v:
Scientific Reports. 8/26/2016, p31732. 1p.
The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood–brain barrier (BBB). Many factors are therefore critic
The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood –brain barrier (BBB). Many factors are therefore criti